Nuclidium AG

Development of copper-based therapeutics and companion diagnostics for precision oncology, including clinical programmes against prostate cancer, metastatic breast cancer and neuroendocrine tumours.

Proprietary platform for diagnostic and therapeutic copper-based radiopharmaceuticals with Cu-61 and Cu-67 radionuclides, targeted molecules and improved production and distribution.

Set-up and operation of a production and supply network for copper-based radiopharmaceuticals with scalable manufacturing, reliable supply and distribution in Europe and North America.

Network for isotope producers, clinicians, researchers and industry partners to exchange data, coordinate supply and promote the clinical use of Cu radiotheranostics.